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Purpose: To compare the effectiveness of the intravenous (IV) and intraosseous (IO) routes 
for drug administration in adults with a cardiac arrest enrolled in the Pre-Hospital 
Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug Administration 
in Cardiac Arrest (PARAMEDIC2) randomised, controlled trial. 
Methods: Patients were recruited from five National Health Service Ambulance Services in 
England and Wales from December 2014 through October 2017. Patients with an out of 
hospital cardiac arrest who were unresponsive to initial resuscitation attempts were 
randomly assigned to 1 mg adrenaline or matching placebo. Intravascular access was 
established as soon as possible, and IO access was considered if IV access was not possible 
after two attempts. 
Results: Among patients with out of hospital cardiac arrest, 3631 received adrenaline and 
3686 received placebo. Amongst these, 1,116 (30.1%) and 1,121 (30.4%) received the study 
drug via the IO route. The odds ratios were similar in the IV and IO groups for return of 
spontaneous circulation (ROSC) at hospital handover (adjusted odds ratio (aOR) 4.07 (95% CI 
3.42-4.85) and (aOR 3.98 (95% CI 2.86-5.53), p value for interaction 0.90); survival to 30 days 
(aOR 1.67 (1.18-2.35) versus 0.9 (0.4-2.05), P=0.18); and favourable neurological outcome 
(aOR 1.39 (0.93-2.06) versus 0.62 (0.23-1.67), P=0.14). 
Conclusion: There was no significant difference in treatment effect (adrenaline versus 
placebo) on ROSC at hospital handover between drugs administered by the intraosseous 
route or by the intravenous route. We could not detect any difference in the treatment 
effect between the IV and IO routes on the longer-term outcomes of 30-day survival or 
favourable neurological outcome at discharge. (ISRCTN73485024) 
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Current resuscitation guidelines recommend the delivery of drugs via the intraosseous (IO) 
route only if intravenous (IV) access is difficult or impossible [1]. A variety of drugs and fluids 
can be delivered via the IO route. Animal studies provide proof of concept that common 
cardiac arrest drugs such as adrenaline [2][3] and amiodarone [4], administered via the IO 
route reach the systemic circulation during cardiac arrest.  Pharmacokinetic studies show 
similar peak drug concentrations (Cmax) and time to peak drug concentrations (Tmax) 
between drugs administered via a central vein and sternal IO [5]. Compared with peripheral 
IV administration, sternal and humeral IO administration resulted in similar Cmax and Tmax 
values [6, 7], whilst tibial IO administration appeared less effective in some [6, 8] but not all 
studies [4, 9]. By contrast, the effect of IO drugs on return of spontaneous circulation (ROSC) 
appears similar to the IV route in both hypovolaemic [3, 9] and ventricular fibrillation 
cardiac arrest models [8, 10, 11]. Although resuscitation guidelines favour IV rather than IO 
access, IO may enable more rapid delivery of resuscitation drugs: in a randomised clinical 
trial, the first attempt success rate was higher with the tibial IO route than with peripheral 
IV (or humeral IO) route [12].  
 
Several clinical observational studies have documented an association between use of the 
IO route and a lower likelihood of return of spontaneous circulation (ROSC) [13-15], survival 
to hospital admission [13], survival to hospital discharge [14], and favourable neurological 
outcome [14]. In contrast, one observational study showed that rates of ROSC at the time of 
emergency department arrival among out-of-hospital cardiac arrest patients in whom IO 
access was attempted first were non-inferior to those in whom IV access was attempted 
first [16].  
 
In a multicentre double-blinded controlled trial of adrenaline versus placebo in out-of-
hospital cardiac arrest (PARAMEDIC-2) [17], emergency medical services (EMS) personnel 
delivered the study drug according to ambulance clinical practice guidelines which state that  
IV access should be established as soon as possible and IO should be considered if IV access 
is not possible after two attempts [18]. The trial, which includes patients receiving 
adrenaline or placebo, provides the opportunity for unique insights into the effectiveness or 
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otherwise of the IO route. The objective of this paper was to explore the effect of IV and IO 
routes for drug delivery on the primary (survival at 30 days) and secondary outcomes (ROSC 
at handover to hospital, survival at hospital discharge and favourable neurological outcome 
at hospital discharge). 
 
Methods 
Trial design and participants 
PARAMEDIC2 was a multicentre double-blinded placebo-controlled trial conducted by five 
National Health Service (NHS) ambulance services in the United Kingdom (UK) from 
December 2014 to October 2017 inclusive [17]. Participants treated for out of hospital 
cardiac arrest who were not successfully resuscitated by means of defibrillation and/or CPR, 
and who met predetermined eligibility criteria were randomly allocated to either adrenaline 
or saline placebo. Randomisation occurred when trial paramedics opened packs containing 
prefilled syringes loaded with either ten 1 mg doses of adrenaline or ten doses of 0.9% 
saline. Trial packs and their contents were identical in appearance and carried a unique 
identification number. In all other respects identical paramedic resuscitation protocols were 
followed. Randomisation of drug packs to ambulance services was achieved using the 
minimisation method with an allocation ratio of 1:1. Participants, paramedics and trial staff 
were blinded to treatment allocation. A full description of trial methods has been previously 
published [19]. When IO access was attempted, no specific site was recommended by UK 
paramedic practice guidelines. Most UK ambulance services train their paramedics in 
proximal tibial, or proximal humerus IO access.  
 
Data 
The primary aim of this study was to assess the baseline characteristics and outcome 
measures for participants who had received two drug administration modes: IV and IO, in 
the PARAMEDIC2 study. The European Resuscitation Council (ERC) resuscitation guidelines 
and UK paramedic practice guidelines recommend the use of IO only if IV is difficult or 
impossible to establish [1, 18].  Data collected prior to and at the scene of the cardiac arrest 
include: age, gender, initial rhythm, aetiology, witnessed, bystander CPR, time from 
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emergency call to trial drug administration, time from emergency call to emergency medical 
services (EMS) personnel arrival, time from EMS personnel arrival to trial drug 
administration, time on scene, time transported to hospital, survival at scene, ROSC at any 
time and ROSC at the point of hospital handover. Analyses assessed the primary outcome: 
survival at 30 days, and secondary outcomes: ROSC at handover to hospital, survival at 
hospital discharge and favourable neurological outcome at hospital discharge. The 
neurological outcome was measured using a modified Rankin scale assessment (ranging 
from 0 [no symptoms] to 6 [death]) where a score of 0-3 inclusive was considered 
favourable [20].  
 
Statistical analysis 
This study was pre-specified prior to the final data lock but not defined in the statistical 
analysis plan. The outcomes were analysed using the modified intention-to-treat 
population, which excluded those with missing outcome or unspecified drug administration 
route data, i.e. administration by both or unspecified routes. Patients with missing covariate 
data were also excluded from the adjusted analysis. Baseline characteristics were 
summarised using mean and standard deviation (SD) or median and interquartile range 
(IQR) for continuous variables. Baseline difference was reported with 95% confidence 
interval (CI) and tested using t test. For categorical variables, the number and percentage of 
participants were detailed, and baseline difference was assessed using Chi-squared test. 
Fisher’s exact test was not used due to a long calculation time.  
Treatment effect by the routes was assessed in each of the pre-specified outcomes using 
unadjusted and adjusted logistic regression models. Adjustment was made for categorical 
variables including gender, whether a bystander commenced CPR, witness to the arrest, 
aetiology, initial rhythm and continuous variables including age, interval between 
emergency call and ambulance arrival at scene, and interval between ambulance arrival and 
drug administration. The interaction between two categorical variables, treatment and 
administration route, was tested in all models. Unadjusted and adjusted odds ratios (uOR 
and aOR, respectively) were reported with 95% CI, as well as p-values for the interactions.  
The primary outcome was also assessed by stratification of treatment and trial drug delivery 
route using Kaplan-Meier plot and Cox regression. The route and treatment interaction was 
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assessed and the adjusted hazard ratio (aHR) with 95% CI and p-value for interaction were 
reported. As the proportional hazards assumption was not met, we reported the adjusted 
results by survival within one day and over one day. All statistical analyses were undertaken 
using SAS version 9.4 (SAS Institute, Cary NC). 
The trial was funded by the Heath Technology Assessment Programme of the National 
Institute for Health Research (NIHR). The funders had no role in the trial design, data 
collection or analysis, or in the writing of this report. The Warwick Clinical Trials Unit 
undertook data management activities. The trial statisticians assume responsibility for the 




Of 8,014 participants enrolled in the study, 697 (8.7%) had missing or unclear route of drug 
administration data, leaving 3,631 (90.4% of those randomised to adrenaline) and 3,686 
(92.2% of those randomised to placebo) on each arm. Of these, 1,116 (30.7%) and 1,121 
(30.4%) in the adrenaline and placebo arms respectively received the study drug via the IO 
route. The rest were given the drug via the IV route. The primary outcome data were 
recorded for 3,629 participants (99.9%) in the adrenaline arm and 3,682 (99.9%) in the 
placebo arm. A CONSORT diagram illustrates the number of participants lost to follow-up for 
each of the four outcomes (Figure 1). 
Table 1 shows the baseline characteristics of participants by IV and IO route. Trial drug was 
administered via IO to more young, female and unwitnessed participants with a non-
shockable rhythm and a longer time to treatment. The electronic supplementary material 
(Table e1) reports the unadjusted outcomes according to route of administration.  
 
Results of adjusted analyses for the trial outcomes are presented in Figure 2. The odds ratios 
(adrenaline versus placebo) for ROSC at hospital handover were similar in the IV (aOR 4.07 
(95% CI 3.42-4.85) and IO groups (aOR 3.98 (95% CI 2.86-5.53)), p value for interaction 0.90. 
The confidence intervals for survival (discharge and 30 days) and favourable neurological 
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outcomes for IV and IO also overlapped, with no statistical evidence of an interaction. The 
unadjusted results are shown in the Appendix Figure 1.  By removing time from ambulance 
arrival to drug administration from the adjusted analysis (Appendix Figure 2), the odds ratios 
of treatment increased in the IV route and decreased in the IO route suggesting some of the 
differences in the outcomes have been explained by the time interval between ambulance 
arrival and drug administration. 
 
Figure 3 presents the cumulative survival to 30-days for the IV and IO routes for both 
adrenaline and placebo.  The survival curves are higher for the IV route than for the IO route 
in both the adrenaline and placebo arms, but the confidence intervals overlap and there 
was no statistical evidence of an interaction in both periods (within and over one day 
survival) (adjusted Cox regression model p=0.70 and 0.50, respectively). The aHR of IV 
versus IO within one day survival was 1.02 (95% CI: 0.94, 1.10) in adrenaline and 1.00 (0.93, 
1.08) in placebo and the aHR over one day survival was 1.30 (95% CI: 0.98, 1.72) in 
adrenaline and 1.08 (0.68, 1.71) in placebo. 
 
Discussion 
In this secondary analysis of the PARAMEDIC-2 trial we have shown that the treatment 
effect of adrenaline (versus placebo) on ROSC at hospital admission was the same when 
given by the IV and IO routes. We could not detect any difference in the treatment effect 
between the IV and IO routes on the longer-term outcomes of 30-day survival or favourable 
neurological outcome at discharge.  
The strength of this study is that the substantial treatment effect of adrenaline on ROSC and 
the inclusion of a placebo arm in the PARAMEDIC-2 trial enables a robust statistical 
approach that adjusts reliably for the large differences in time to drug delivery between the 
IV and IO routes. The large treatment effect of adrenaline on ROSC will have enabled us to 
detect relatively small differences in the efficacy of adrenaline between the IV and IO routes 
of administration.  Our approach of assessing for heterogeneity of treatment effects with a 
statistical test for interaction, rather than undertaking separate tests of treatment effect in 
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each sub-group follows best practice guidelines and reduces the risk of mistakenly claiming  
a difference where it may not exist [21]. 
During prehospital resuscitation, in many settings the IO route is generally attempted only 
after attempts at IV access have failed or if IV access is likely to be very difficult or 
impossible. Thus, in comparison with the IV route, the time to drug delivery with the IO 
route is inevitably much longer (Table 1) and, as a result of resuscitation time bias [22], the 
IO route appears to be associated with worse outcomes even in the placebo group. 
Regardless of the route of delivery, small volumes of saline (placebo) will have no effect on 
ROSC, and the placebo arm of the PARAMEDIC-2 trial enabled the best possible adjustment 
for confounding by resuscitation time bias. The gold standard for eliminating resuscitation 
time bias would be a randomised clinical trial (RCT) comparing the IV versus IO drug route, 
although such a trial would not allow the treatment arm to be blinded.  
Several other observational studies have reported outcomes following IO versus IV drug 
delivery and except for one [16] these all report an association between IO access and 
decreased rate of ROSC [13-15]. In a retrospective cohort study, the clinical outcomes of 
1800 OHCA patients treated by the EMS in Seattle were analysed according to the route of 
delivery of the first EMS drug administered (IV or IO) [13]. In multivariable adjusted 
analyses, compared with the IV-treated patients, the 275 IO-treated patients (15.3%), had a 
lower likelihood of ROSC (OR 0.67, 95% CI 0.50 to 0.88) but IO treatment was not associated 
with survival to discharge (OR 0.81, 95% CI 0.55 to 1.21, p=0.31) The call to vascular access 
interval was available for about two-thirds of the full cohort and a sensitivity analysis 
confined to these patients produced results that were similar to the overall cohort. 
Like our study, two of the previous studies are secondary analyses of RCTs. In a secondary 
analysis of the Resuscitation Outcomes Consortium Prehospital Resuscitation Using an 
Impedance Valve and early Versus Delayed (ROC PRIMED) study, 5% of 13,155 included 
OHCAs received IO access [14]. On multivariable regression, IO access was associated with 
decreased probability of ROSC (OR 0.60; 95% CI 0.49 to 0.74), survival (OR 0.44; 95% CI 0.35 
to 0.76), and favourable neurological outcome (OR 0.24; 95% CI 0.13 to 0.46); however, this 
study did not include data on the time of vascular access or the time of first adrenaline use.  
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In a secondary analysis of the Continuous Chest Compression (CCC) study, which did include 
time to vascular access and drug administration, IO access was initially attempted in 15.5% 
of 19,731 OHCA patients [15]. A propensity analysis was undertaken on 2279 patients with 
initially attempted IO access matched with 2279 patients with initially attempted IV access. 
In the propensity score matched cohort, the rates of sustained ROSC were significantly 
lower in the attempted IO group compared with the attempted IV group (18.2% versus 
22.5%, p<0.001; adjusted OR 0.72 95% CI 0.61 to 0.85); there was no difference in rates of 
survival to hospital discharge or survival with favourable neurological outcome. In contrast 
to several other observational studies, this secondary analysis of the CCC study documented 
slightly faster time to access and drug administration among those in whom IO was initially 
attempted. However, among the initial IV attempts, 1178 (7.1%) failed and these patients 
successfully received IO access. A sensitivity analysis based on eventual successful access 
showed that patients receiving successful IO access had significantly lower rates of 
sustained ROSC (adjusted OR 0.73, 95% CI 0.66 to 0.81, p < 0.001), survival to hospital 
discharge (adjusted OR 0.77, 95% CI 0.63 to 0.93, p = 0.005) and survival with favorable 
neurological function discharge (adjusted OR 0.73, 95% CI 0.58 to 0.93, p < 0.01) compared 
with eventual successful IV access. We also assigned the IO and IV groups based on the 
route that paramedics delivered the study drug, but the methodology of our study is 
different: we looked for evidence of an interaction in the treatment effect according to 
whether adrenaline or placebo were administered via the IV or IO routes. The result 
(interaction p >0.05) in our study did not find evidence of a difference between IV and IO. 
Thus, the apparent conflict between the results of our study and that of the secondary 
analysis of the CCC study probably reflects the different methodologies. The inclusion of 
patients receiving placebo via IO and IV routes may have enabled us to achieve more 
complete statistical elimination confounding. 
A retrospective chart review of three EMS agencies documented that among 1310 OHCA 
patients receiving adrenaline first via the IO route (48.6%), this route was non-inferior to IV 
first for the end point of ROSC on emergency department arrival (18.6% versus 20.9%; OR 
0.86, 95% CI 0.66 to 1.13) [16].  In this study, the first attempt success rate for IO access was 
higher than for IV access (94.8% versus 81.6%, p<0.01). Although the site of IO needle 
placement was not documented, only one of the three EMS agencies allowed humeral head 
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IO placement; thus, the majority of IO needles were placed in the tibia. In a RCT enrolling 
182 OHCA patients, tibial IO access had a higher first-attempt success than either humeral 
IO or peripheral IV access [12]. We did not document the IO site used in the PARAMEDIC2 
study, but it is possible that differences in the IO site used could account partly for some of 
the variation in results documented in all these observational studies. Among observational 
studies, we have documented the largest proportion of patients receiving drugs via the IO 
route, which is probably a reflection of the contemporary cohort of patients in our study 
against a background of increasing use of the IO route. 
 
Limitations 
Our study has several limitations. First, it is a secondary analysis of an RCT, and the route of 
drug administration was not randomised; thus, we can show only an association between 
route of drug delivery and the treatment effect. However, we believe that inclusion of 
placebo groups allowed us to reduce the influence of confounding variables including 
resuscitation time bias. Second, we have no data on previous attempts at IV access but, 
given that paramedics were instructed to use the IO route only if the IV route was not 
possible, it is likely that most of the patients in the IO group had had previous failed 
attempts at IV access. Third, we were unable to adjust for the unobserved data related to 
this delay, such as difficulty of access linked to co-morbidities, obesity, vasculopathy, and 
cause e.g. hypovolaemia. Fourth, for this reason, our study also does not address the 
question of which access route should be attempted first. Fifth, we did not have information 
about the IO access site, and this may influence the rate and reliability of delivery of 
adrenaline. Additionally, the number of survivors at hospital discharge and number with a 
favourable neurological outcome who received drug via the IO route were small, which 
limits the precision of our findings.  Finally, our study included only adults and therefore 





In this secondary analysis of the PARAMEDIC-2 trial the treatment effect of adrenaline 
(versus placebo) on ROSC at hospital handover was the same when given by the IV and IO 
routes. We could not detect any difference in the treatment effect between the IV and IO 
routes on the longer-term outcomes of survival to discharge/30 days and favourable 
neurological outcome at discharge. The results for 30-day survival and survival with a 
favourable neurological outcome were limited by few events and are therefore inconclusive; 
an adequately powered study is needed to confirm these findings. 
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Figure 1. CONSORT diagram of the analysis by Intravenous and Intraosseous routes. 
 
Figure 2. Adjusted treatment effect and interaction with Intravenous and Intraosseous 
routes on trial outcomes. Note: *, p-value for treatment and route interaction. 
Adjustment was made for age, gender, whether a bystander commenced CPR, witness 
to the arrest, aetiology, initial rhythm, interval between emergency call and ambulance 
arrival at scene, and interval between ambulance arrival and drug administration.  
 
Figure 3. Cumulative survival to 30 days by treatment and trial drug administration 





In this study there was no significant difference in treatment effect (adrenaline versus 
placebo) on ROSC at hospital handover whether drugs were administered by the 
intraosseous or intravenous route. The results for 30-day survival and survival with a 
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Age       
Mean (SD) 70.9 (15.9) 67.5 (17.5) 3.4 (2.5, 4.2) <0.001 
Median (IQR) 74 (21.5) 70 (26.1)   
Missing 7 2   
Gender      <0.001 
Female 1716 (33.8%) 882 (39.4%)   
Male 3364 (66.2%) 1355 (60.6%)   
Missing 0 (0.0%) 0 (0.0%)   
Initial rhythm      <0.001 
Shockable rhythm 1031 (20.3%) 318 (14.2%)   
VF 953 (18.8%) 298 (13.3%)   
Pulseless VT 29 (0.6%) 11 (0.5%)   
AED shockable 49 (1.0%) 9 (0.4%)   
Non-shockable rhythm 3970 (78.1%) 1880 (84.0%)   
Asystole 2695 (53.1%) 1319 (59.0%)   




Bradycardia 24 (0.5%) 10 (0.4%)   
AED nonshockable 46 (0.9%) 21 (0.9%)   
Missing 79 (1.5%) 39 (1.7%)   
Aetiology      <0.001 
Medical 4713 (92.8%) 2038 (91.1%)   
Traumatic cause 59 (1.2%) 41 (1.8%)   
Drowning 12 (0.2%) 7 (0.3%)   
Drug overdose 72 (1.4%) 65 (2.9%)   
Electrocution 0 (0.0%) 1 (0.0%)   
Asphyxial 126 (2.5%) 56 (2.5%)   
Missing 98 (1.9%) 29 (1.3%)   
Occurrence witnessed      0.004 
Unwitnessed 1862 (36.7%) 897 (40.1%)   
EMS witnessed 572 (11.3%) 278 (12.4%)   
Bystander witnessed 2599 (51.2%) 1043 (46.6%)   
Missing 47 (0.9%) 19 (0.8%)   
Bystander commenced CPR      <0.001 
Bystander CPR 3100 (61.0%) 1226 (54.8%)   




Not applicable (for EMS 
witnessed) 572 (11.3%) 278 (12.4%) 
  
Missing 88 (1.7%) 24 (1.1%)   
Time from 999 call to treatment      <0.001 
<10 min 367 (7.2%) 88 (3.9%)   
10-20 min 2026 (39.9%) 677 (30.3%)   
>20 min 2644 (52.0%) 1460 (65.3%)   
Missing 43 (0.8%) 12 (0.5%)   
Mean (SD) 21.6 (10.5) 25.4 (12.4) -3.9 (-4.5, -3.3) <0.001 
Median (IQR) 20.4 (10.4) 23.9 (12.6)   
Missing 43 12   
Time from 999 call to At scene 
(minute)     
  
Mean (SD) 7.6 (5.8) 7.0 (6.1) 0.6 (0.3, 0.9) <0.001 
Median (IQR) 6.8 (5.7) 6.3 (5.0)   
Missing 0 0   
Time from At scene to 
Administration of drug 
(minute)     
  




Median (IQR) 12.7 (8.6) 17.0 (10.5)   
Missing 43 12   
Time on scene       
Mean (SD) 47.4 (21.2) 49.5 (19.5) -2.1 (-3.7, -0.5) 0.01 
Median (IQR) 43.9 (23.2) 46.6 (24.0)   
Not applicable because not 
transported  2958 1405 
  
Missing 3 0   
Time transported to hospital       
Mean (SD) 12.9 (9.7) 12.1 (8.7) 0.8 (0, 1.5) 0.04 
Median (IQR) 10.7 (8.7) 10.0 (7.9)   
Not applicable because not 
transported  2958 1405 
  







Appendix Table 1: Unadjusted summary of outcomes by drug delivery route in (a) Adrenaline arm (b) Placebo arm. 
(a) 
  Intravenous (IV) Intraosseous (IO) 
p 
value 
Survival at 30 days       
Alive 104/2513 (4.1%) 13/1116 (1.2%) <0.001 
ROSC at hospital handover       
ROSC 668/2488 (26.8%) 189/1111 (17.0%) <0.001 
Survival at hospital discharge       
Alive 102/2510 (4.1%) 12/1115 (1.1%) <0.001 
Favourable neurological outcome at hospital discharge       
Good (0-3) 71/2509 (2.8%) 7/1115 (0.6%) <0.001 
 
(b) 
  Intravenous (IV) Intraosseous (IO) 
p 
value 
Survival at 30 days       
Alive 67/2561 (2.6%) 13/1121 (1.2%) 0.005 
ROSC at hospital handover       
ROSC 223/2557 (8.7%) 57/1115 (5.1%) 0.008 
Survival at hospital discharge       
Alive 65/2562 (2.5%) 13/1120 (1.2%) <0.001 
Favourable neurological outcome at hospital discharge       
Good (0-3) 53/2561 (2.1%) 11/1120 (1%) 0.02 
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